Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer

Generated Narrative: Group 179619

version: 4; Last updated: 2023-12-06 00:11:33+0000

Profile: SystematicReviewEligibilityCriteria

Artifact related artifact: No display for RelatedArtifact (type: cite-as; citation: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-04. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619.)

Artifact Author: Brian S. Alper:

Artifact Title: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer

Artifact URL: https://fevir.net/resources/Group/179619

Artifact Publisher: Computable Publishing LLC

Artifact Copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

Artifact use context: Evidence Communication = SystematicReviewEligibilityCriteria

Artifact Contact: support@computablepublishing.com

org/fhir/uv/ebm/StructureDefinition/combination-method: all-of

Artifact Status: active

identifier: FEvIR Object Identifier/179619

name: SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer

description:

Study selection criteria Types of Studies. Randomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.

Types of participants. Patients aged ≥18 years with cytological or histological diagnosis of mHNPC.

type: Animal

membership: Definitional

characteristic

org/fhir/uv/ebm/StructureDefinition/characteristic-description:

Randomized controlled clinical trials (RCTs)

code: Study Design

value: randomized assignment

exclude: false

characteristic

org/fhir/uv/ebm/StructureDefinition/characteristic-description:

parallel design

code: Study Design

value: Parallel cohort design

exclude: false

characteristic

org/fhir/uv/ebm/StructureDefinition/characteristic-description:

compared the association of ADT and chemotherapy (docetaxel), versus ADT alone

code: Comparison

value: GroupAssignment: ADT plus docetaxel vs. ADT alone

exclude: false

characteristic

org/fhir/uv/ebm/StructureDefinition/characteristic-description:

Types of participants. Patients aged ≥18 years

org/fhir/uv/ebm/StructureDefinition/characteristic-method: applied to participants in the studies

code: Age

value: >=18 years (Details: UCUM codea = 'a')

exclude: false

characteristic

org/fhir/uv/ebm/StructureDefinition/characteristic-description:

Types of participants. Patients with cytological or histological diagnosis of mHNPC.

org/fhir/uv/ebm/StructureDefinition/characteristic-method: applied to participants in the studies

org/fhir/uv/ebm/StructureDefinition/characteristic-method: cytological or histological diagnosis

code: Disease (disorder)

value: metastatic hormone-naive prostate cancer

exclude: false